Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC

◆ TRIAL DATA

Research comparing dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H (microsatellite instability-high) metastatic colorectal cancer. (Clinical Colorectal Cancer)